Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m Newly Diagnosed AML Treated with IVO + AZA in the AGILE Study

Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.

Video Player is loading.
Current Time 0:00
Duration 16:28
Loaded: 0%
Stream Type LIVE
Remaining Time 16:28
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

x